JAK2 and essential thrombocythemia: The median JAK2 V617F allele burden in secondary MF (post-PV MF and post-ET MF: 92.6% and 62.6%, respectively) is significantly higher compared to PMF (48.8%), and nearly all post-PV MF patients harbor mutated JAK2 [69,70].